LC
ACET icon

Lindbrook Capital’s Adicet Bio ACET Stock Holding History

Lindbrook Capital’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5
Closed -$438 – 2705
2023
Q1 		$438 Buy
+5
New +$627 ﹤0.01% 2631
2022
Q4 		– Sell
-12
Closed -$3K – 2823
2022
Q3 		$3K Buy
12
+11
+1,100% +$2.79K ﹤0.01% 1824
2022
Q2 		$0 Buy
+1
New +$220 ﹤0.01% 2458

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Lindbrook Capital's ACET Position: Q2 2023 in Review

Lindbrook Capital sold out of Adicet Bio (ACET) in Q2 2023, closing a stake of 5 shares — an estimated $438 sold.

Lindbrook Capital first reported a position in ACET in Q2 2022 and held it in 3 quarters. The position peaked at $3K in Q3 2022. 94 funds tracked by Wall St. Rank hold ACET as of Q2 2023.

  • Lindbrook Capital reported no remaining Adicet Bio position as of Q2 2023 after selling out during the quarter.
  • Lindbrook Capital sold 5 Adicet Bio shares in Q2 2023, an estimated $438.
  • Lindbrook Capital first reported a position in Adicet Bio in Q2 2022 and held it in 3 quarters.
  • Lindbrook Capital's Adicet Bio position peaked at $3K in Q3 2022.
  • 94 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.